All new ventures are risky (if it were easy, everyone would do it!). In the medical device industry, new ventures are faced with many unknowns – funding, the FDA, reimbursement, customer (medical professional) acceptance, end user acceptance, etc. Yet every month, an industrious entrepreneur with an idea believes he or she will start in a basement workshop, overcome all the obstacles and build the next Boston Scientific or Medtronic. How does this happen? What criteria are used to evaluate new medical device opportunities? How important is the technology? the management team? the size of the market? In short, how do investors or companies determine the best path forward when evaluating these opportunities?
Please join the group as their distinguished panel takes on this multi-faceted discussion. They will look at risk assessment from the point of view of investors as well as corporate strategy decision makers.
Panelists:
John McDonough, CEO, T2 Biosystems
Richard Burtt, Mass Medical Angels (MA2)
Chuck Dockendorff, Executive VP and CFO, Covidien
Moderator:
Chris Palatucci, PhD Partner, Palatucci Executive Search, LLC
Who Should Attend
- Individuals in the MDG community who want to better understand what it takes to start a medical device company
- People who have positions in med device/life sciences – and want to grow their careers
- People who serve this med device world – and are seeking more direct understanding of risk analysis
- People who do not have jobs in this field – and want to understand the risks and rewards here
Registration Fee:
Members: $25 (PrePaid), $35 at the door
Non-Members: $35 (PrePaid), $45 at the door